Last edition
News about
Medidata Launches Next-Gen AI Imaging Solution for Faster Clinical Trials
Medidata unveiled next-generation AI-powered imaging capabilities within the Medidata Data Experience at ASCO 2026, enabling faster, more precise clinical trials.
EMA Recommends XFG-Targeted COVID-19 Vaccines for 2026-2027 Immunisation Campaign
The European Medicines Agency’s Emergency Task Force has recommended updating COVID-19 vaccines to target the XFG variant for the 2026–2027 vaccination season, aiming to enhance protection against circulating SARS-CoV-2 strains.
The Colorectal Cancer Alliance and the Global Coalition for Adaptive Research have partnered to launch KLEOS, a pioneering adaptive clinical trial platform designed to accelerate the development of new therapies for colorectal cancer and improve patient outcomes.
Leica Biosystems, AstraZeneca and Daiichi Sankyo have expanded their strategic collaboration to develop an AI-enabled immunohistochemistry assay and computational pathology solution for evaluating the TROP2 Normalised Membrane Ratio biomarker in NSCLC, aiming to advance biomarker-driven cancer research and future precision medicine approaches.<br />
CARES Phase 3 Trial Highlights Anselamimab Potential in Kappa Light Chain Amyloidosis
Anselamimab demonstrated promising efficacy in the phase 3 CARES programme, showing a 62 percent improvement in survival and a 71 percent reduction in cardiovascular hospitalisations among patients with kappa light-chain amyloidosis, despite the study not meeting its primary endpoint in the overall light-chain amyloidosis population.
UK MHRA Approves Rilzabrutinib for Adults with Immune Thrombocytopenia
Rilzabrutinib has been authorised in the UK for the treatment of adults with immune thrombocytopenia who have had an insufficient response to previous therapies, providing a new treatment option for this rare autoimmune bleeding disorder. The UK MHRA will continue to closely monitor the medicine’s safety and effectiveness following approval.
Tempus Launches Next-Generation Lens AI Platform for Oncology Drug Development
Tempus has unveiled the next-generation Lens platform, expanding its agentic AI capabilities for oncology drug development by leveraging over a decade of longitudinal real-world data and advanced analytics to generate actionable insights for biopharma research, clinical development, and precision medicine.
Pfizer's BRAFTOVI Nearly Doubles Progression-Free Survival in Metastatic Colorectal Cancer
Pfizer reported phase 3 BREAKWATER trial results showing that the BRAFTOVI regimen nearly doubled median Progression-Free Survival (PFS) in patients with metastatic colorectal cancer, reducing the risk of disease progression or death by 56 percent and the risk of death by 44 percent compared with standard chemotherapy in BRAF V600E-mutant disease.
Marksans Pharma Acquires Netherlands-Based QliniQ B.V. to Strengthen Europe Business
Marksans Pharma is set to acquire Netherlands-based QliniQ BV, a strategic move that expands its footprint in regulated European markets and strengthens its forward-integration strategy through direct market-access capabilities across the European Union (EU).
US FDA Grants Breakthrough Therapy Designation to Calderasib for KRAS G12C-Mutant NSCLC
Calderasib has received US FDA Breakthrough Therapy Designation for certain patients with newly diagnosed metastatic KRAS G12C-mutant Non-Small Cell Lung Cancer (NSCLC), supported by promising phase 1 KANDLELIT-001 trial data highlighting its potential as a next-generation, highly potent and selective KRAS G12C inhibitor.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy